. 2019 Aug 10;11(8):1859. doi: 10.3390/nu11081859

Table 3.

Sleep measurements.

Parameters	Treatment	Values *
Parameters	Treatment	Week 0	Week 24	Changes
Total N3 stage (min)	CP2305	41.6 ± 5.0	46.1 ± 5.3	4.5 ± 3.4
	Placebo	43.9 ± 4.9	46.1 ± 5.2	2.2 ± 3.3
Total REM sleep time (min)	CP2305	93.4 ± 5.7	84.8 ± 5.7	−8.5 ± 5.5
Total REM sleep time (min)	Placebo	79.4 ± 5.6	81.8 ± 5.6	2.4 ± 5.4
Delta power in total sleep period time (μV2)	CP2305	520,644 ± 61,030	483,302 ± 54,273	−37,342 ± 25,529
Delta power in total sleep period time (μV2)	Placebo	482,451 ± 59,889	456,930 ± 53,259	−25,522 ± 25,052
Delta power ratio (%) ^†,‡	CP2305	37.2 ± 2.7	50.4 ± 2.9	13.2 ± 2.9
	Placebo	41.2 ± 2.6	44.4 ± 2.9	3.2 ± 2.8
Sleep latency of first N3 stage (min) ^†	CP2305	23.7 ± 3.6	17.6 ± 5.6	−6.0 ± 5.4
Sleep latency of first N3 stage (min) ^†	Placebo	22.0 ± 3.5	26.3 ± 5.5	4.3 ± 5.3
Wake time after sleep onset (min) ^†	CP2305	22.7 ± 2.1	18.4 ± 2.1	−4.2 ± 2.0
Wake time after sleep onset (min) ^†	Placebo	22.7 ± 1.0	21.8 ± 2.1	−0.9 ± 1.9

* Data are presented as the mean ± SEM. ^† Significant differences between CP2305 and placebo group (p < 0.05) by analysis of covariance (ANCOVA) with each initial value as a covariate. Partial eta squared values of delta power ratio, sleep latency of first N3 stage, and wake time after sleep onset are 0.099, 0.085, and 0.120, respectively. ^‡ Delta power ratio is representative of the delta power in the first sleep cycle relative to the delta power in the total sleep period. Abbreviations: REM, rapid eye movement; N3, non-REM sleep stage 3.